We have demonstrated earlier that PPARγ agonists ameliorate experimental allergic encephalomyelitis (EAE) model of MS by blocking inflammatory signaling networks [39], suggesting a physiological role for the PPARγ in the regulation of inflammation and CNS repair in neurodegenerative diseases. This evidence concerns the gene PPARG and neurodegenerative disease.